Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.’s share was trading at $8.67 as of April 20th. NVAX’s trailing P/E was 3.36 according to Yahoo Finance.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. NVAX is positioned as a deeply misunderstood vaccine company that the market continues to value as a distressed, high burn COVID-era manufacturer, despite its structural transition into an asset-light vaccine IP and licensing platform.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The current bullish thesis centers on a clear variant perception: investors are underestimating the impact of the May 2024 Sanofi partnership, which effectively offloads manufacturing and commercial execution while converting Novavax into a high-margin royalty and milestone-driven business.
This shift has already begun to materialize through meaningful milestone payments and royalty streams tied to Nuvaxovid and Matrix M applications, lowering the company’s break-even profile by roughly 60% and providing a more stable valuation floor even in a low vaccine uptake environment. Additional validation came from the January 2026 Pfizer agreement for Matrix M, further reinforcing the platform’s value beyond COVID and into broader infectious disease and potentially oncology applications.
The near-term catalyst is the Phase 3 readout of the COVID-Influenza Combination (CIC) vaccine expected in late 2026, which represents the company’s entry into the large seasonal respiratory vaccine market. If successful, the CIC vaccine could unlock a multi-billion-dollar opportunity by bundling flu and COVID protection into a single shot, supported by Sanofi’s global distribution network.
The platform’s core advantage lies in its recombinant protein nanoparticle design combined with the Matrix M adjuvant, which enhances immune response while maintaining strong stability at standard refrigeration temperatures, offering a logistical edge over mRNA competitors.
Financially, Novavax has meaningfully de-risked its balance sheet, ending FY2025 with $751 million in cash, $1.12 billion in revenue, and significantly reduced operating costs following aggressive restructuring. The company has transitioned from a cash-burning developer into a leaner licensing model with improving profitability and milestone-driven upside.
The bull case assumes successful CIC approval, rapid adoption in the seasonal vaccine market, and continued expansion of Matrix M licensing deals, driving substantial re-rating potential toward the $22 target. In contrast, failure of the Phase 3 program or weaker-than-expected uptake would compress valuation toward its cash-backed IP floor, highlighting a binary but highly skewed risk-reward setup.
Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted rising infectious disease tail risks, institutional accumulation, technical momentum, and options flow-driven upside. MRNA’s stock price has appreciated by approximately 64.03% since our coverage. BioEquity Watch shares a similar view but emphasizes Novavax’s structural shift from a COVID-era vaccine manufacturer to an asset-light licensing platform, driven by Sanofi and Pfizer partnerships and a late-2026 CIC catalyst.
Novavax, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held NVAX at the end of the fourth quarter which was 23 in the previous quarter. While we acknowledge the risk and potential of NVAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
